Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin is critical for the regulation of de novo fatty acid synthesis, which converts glucose to lipid in the liver. However, how insulin signals are transduced into the cell and then regulate lipogenesis remains to be fully understood. Here, we identified
CREB/ATF bZIP transcription factor
(
CREBZF
) of the activating transcription factor/cAMP response element-binding protein (ATF/CREB) gene family as a key regulator for lipogenesis through insulin-Akt signaling. Insulin-induced gene 2a (Insig-2a) decreases during refeeding, allowing sterol regulatory element binding protein 1c to be processed to promote lipogenesis; but the mechanism of reduction is unknown. We show that Insig-2a inhibition is mediated by insulin-induced
CREBZF
.
CREBZF
directly inhibits transcription of Insig-2a through association with activating transcription factor 4. Liver-specific knockout of
CREBZF
causes an induction of Insig-2a and Insig-1 and resulted in repressed lipogenic program in the liver of mice during refeeding or upon treatment with streptozotocin and insulin. Moreover, hepatic
CREBZF
deficiency attenuates
hepatic steatosis
in high-fat, high-sucrose diet-fed mice. Importantly, expression levels of
CREBZF
are increased in livers of diet-induced insulin resistance or genetically obese ob/ob mice and humans with
hepatic steatosis
, which may underscore the potential role of
CREBZF
in the development of sustained lipogenesis in the liver under selective insulin resistance conditions.
...
PMID:Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in diet-induced insulin-resistant mice. 2963 72